Optimisation of Immunosuppression Post-Lung Transplantation

Lung transplant recipients traditionally have poorer outcomes compared to other solid organ transplants. Maintenance immunosuppression is typically taken lifelong to prevent rejection of the graft. However, maintenance immunosuppression is associated with significant toxicities that can cause significant morbidity and mortality. Everolimus, the focus of the PhD, is utilized as a second line agent when standard immunosuppression cannot be tolerated. The thesis consists of a series of studies evaluating patient outcomes when everolimus is utilized as a second line agent for maintenance immunosuppression when standard immunosuppression cannot be tolerated.